Nathaniel B. Langer, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Valve Prosthesis Implantation | 5 | 2022 | 1537 | 0.980 |
Why?
|
| Aortic Valve Stenosis | 6 | 2023 | 1965 | 0.930 |
Why?
|
| Heart Valve Prosthesis | 2 | 2022 | 1490 | 0.790 |
Why?
|
| Aorta | 2 | 2018 | 2062 | 0.710 |
Why?
|
| Mitral Valve Stenosis | 2 | 2018 | 376 | 0.690 |
Why?
|
| Heart Arrest, Induced | 1 | 2019 | 355 | 0.620 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2022 | 579 | 0.620 |
Why?
|
| Vascular System Injuries | 2 | 2018 | 250 | 0.570 |
Why?
|
| Chest Tubes | 1 | 2016 | 150 | 0.520 |
Why?
|
| Heart Injuries | 1 | 2017 | 210 | 0.500 |
Why?
|
| Atrial Appendage | 1 | 2018 | 283 | 0.500 |
Why?
|
| Aortic Aneurysm | 1 | 2018 | 644 | 0.470 |
Why?
|
| Coronary Occlusion | 1 | 2016 | 304 | 0.430 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2016 | 549 | 0.430 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2023 | 2073 | 0.410 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2016 | 1066 | 0.380 |
Why?
|
| Device Removal | 1 | 2016 | 656 | 0.380 |
Why?
|
| Heart Ventricles | 3 | 2018 | 3817 | 0.380 |
Why?
|
| Mitral Valve | 2 | 2021 | 1491 | 0.370 |
Why?
|
| Shock, Cardiogenic | 1 | 2016 | 688 | 0.370 |
Why?
|
| Coronary Artery Bypass | 2 | 2019 | 2288 | 0.370 |
Why?
|
| Drainage | 1 | 2016 | 1142 | 0.370 |
Why?
|
| Stroke Volume | 4 | 2023 | 5006 | 0.330 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2018 | 1391 | 0.330 |
Why?
|
| Myocardium | 1 | 2019 | 4772 | 0.280 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2020 | 3537 | 0.250 |
Why?
|
| Aortic Valve | 4 | 2022 | 1924 | 0.250 |
Why?
|
| Atrial Fibrillation | 2 | 2020 | 5035 | 0.230 |
Why?
|
| Heme | 3 | 2014 | 307 | 0.220 |
Why?
|
| Heart Diseases | 1 | 2016 | 2789 | 0.210 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2021 | 1421 | 0.180 |
Why?
|
| Decidua | 1 | 1999 | 86 | 0.170 |
Why?
|
| Mitogens | 1 | 1999 | 232 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 2 | 2018 | 1020 | 0.170 |
Why?
|
| Zebrafish Proteins | 3 | 2009 | 1005 | 0.160 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2018 | 194 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2016 | 5223 | 0.150 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2017 | 110 | 0.150 |
Why?
|
| Reticulocytosis | 1 | 2016 | 10 | 0.140 |
Why?
|
| 5-Aminolevulinate Synthetase | 2 | 2014 | 57 | 0.140 |
Why?
|
| Membrane Transport Proteins | 2 | 2014 | 1031 | 0.140 |
Why?
|
| Hypertension, Pulmonary | 2 | 2017 | 1534 | 0.140 |
Why?
|
| Thoracic Wall | 1 | 2018 | 203 | 0.140 |
Why?
|
| Thoracic Injuries | 1 | 2018 | 272 | 0.130 |
Why?
|
| Endothelium, Vascular | 2 | 2016 | 4459 | 0.130 |
Why?
|
| Mitochondrial Proteins | 2 | 2012 | 994 | 0.130 |
Why?
|
| Aortic Rupture | 1 | 2018 | 312 | 0.130 |
Why?
|
| Homozygote | 2 | 2018 | 1787 | 0.130 |
Why?
|
| Ferrochelatase | 2 | 2012 | 46 | 0.130 |
Why?
|
| Mediastinum | 1 | 2016 | 267 | 0.120 |
Why?
|
| Endocarditis | 1 | 2018 | 349 | 0.120 |
Why?
|
| Iron Regulatory Protein 1 | 1 | 2014 | 36 | 0.120 |
Why?
|
| Porphyrias | 1 | 2014 | 57 | 0.120 |
Why?
|
| Zebrafish | 6 | 2014 | 2996 | 0.120 |
Why?
|
| Capillaries | 1 | 2017 | 773 | 0.120 |
Why?
|
| Equipment Failure | 1 | 2016 | 578 | 0.110 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 591 | 0.110 |
Why?
|
| Receptors, Immunologic | 1 | 1999 | 1423 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 1 | 2021 | 1031 | 0.110 |
Why?
|
| Lung Transplantation | 1 | 2021 | 1155 | 0.110 |
Why?
|
| Heart Atria | 1 | 2018 | 1356 | 0.110 |
Why?
|
| Erythroblasts | 1 | 2012 | 150 | 0.100 |
Why?
|
| Hemoglobins | 2 | 2016 | 1532 | 0.100 |
Why?
|
| Aorta, Thoracic | 1 | 2018 | 1084 | 0.100 |
Why?
|
| Ambulatory Care Facilities | 1 | 2018 | 934 | 0.100 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2018 | 795 | 0.100 |
Why?
|
| Treatment Outcome | 6 | 2022 | 63107 | 0.100 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2017 | 581 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13104 | 0.100 |
Why?
|
| Mitochondria, Heart | 1 | 2013 | 247 | 0.100 |
Why?
|
| Humans | 28 | 2023 | 744366 | 0.100 |
Why?
|
| Cefoxitin | 1 | 2010 | 36 | 0.100 |
Why?
|
| Protoporphyria, Erythropoietic | 1 | 2011 | 43 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2021 | 1591 | 0.090 |
Why?
|
| GATA1 Transcription Factor | 2 | 2009 | 293 | 0.090 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2013 | 560 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2017 | 1223 | 0.090 |
Why?
|
| Anemia, Hemolytic | 1 | 2010 | 168 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2018 | 1476 | 0.090 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2009 | 107 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1677 | 0.080 |
Why?
|
| Protoporphyrinogen Oxidase | 1 | 2008 | 3 | 0.080 |
Why?
|
| Porphyria, Variegate | 1 | 2008 | 3 | 0.080 |
Why?
|
| Anemia, Hypochromic | 1 | 2008 | 66 | 0.080 |
Why?
|
| Erythropoiesis | 1 | 2012 | 706 | 0.080 |
Why?
|
| Cation Transport Proteins | 1 | 2011 | 327 | 0.080 |
Why?
|
| Hospital Mortality | 2 | 2020 | 5316 | 0.080 |
Why?
|
| Mitochondria | 2 | 2012 | 3514 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2018 | 1887 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 6539 | 0.080 |
Why?
|
| Male | 13 | 2022 | 350115 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2017 | 4196 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 2638 | 0.070 |
Why?
|
| Erythroid Cells | 1 | 2008 | 239 | 0.070 |
Why?
|
| Aged | 6 | 2018 | 163288 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 2530 | 0.070 |
Why?
|
| Ventricular Function, Left | 3 | 2023 | 3666 | 0.070 |
Why?
|
| Embryonic Development | 1 | 2009 | 711 | 0.060 |
Why?
|
| Risk Factors | 3 | 2022 | 72296 | 0.060 |
Why?
|
| Myocytes, Cardiac | 1 | 2013 | 1629 | 0.060 |
Why?
|
| Cell Movement | 1 | 2016 | 5218 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2016 | 4576 | 0.060 |
Why?
|
| Female | 12 | 2022 | 380193 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 1085 | 0.060 |
Why?
|
| Megakaryocytes | 1 | 2008 | 545 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 1813 | 0.060 |
Why?
|
| Middle Aged | 7 | 2018 | 213390 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3135 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3242 | 0.050 |
Why?
|
| Adult | 8 | 2021 | 214052 | 0.050 |
Why?
|
| Embryo, Nonmammalian | 3 | 2011 | 895 | 0.050 |
Why?
|
| Cytokines | 1 | 2016 | 7323 | 0.050 |
Why?
|
| Genetic Complementation Test | 2 | 2012 | 562 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2009 | 1178 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3873 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2023 | 77460 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 15078 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8385 | 0.040 |
Why?
|
| Chemical Fractionation | 1 | 1999 | 65 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 9240 | 0.040 |
Why?
|
| Heart Failure | 1 | 2023 | 10895 | 0.040 |
Why?
|
| COS Cells | 2 | 2011 | 1161 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2009 | 3617 | 0.040 |
Why?
|
| Gene Expression | 1 | 2011 | 7798 | 0.040 |
Why?
|
| Viremia | 1 | 2021 | 736 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 18034 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2014 | 11486 | 0.040 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 1999 | 282 | 0.040 |
Why?
|
| Stroke | 1 | 2020 | 9981 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1999 | 599 | 0.040 |
Why?
|
| Proteins | 1 | 2012 | 6100 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1999 | 906 | 0.040 |
Why?
|
| Molecular Weight | 1 | 1999 | 2255 | 0.040 |
Why?
|
| Angiogenic Proteins | 1 | 2017 | 104 | 0.040 |
Why?
|
| France | 1 | 2018 | 517 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2016 | 19233 | 0.040 |
Why?
|
| Sus scrofa | 1 | 2017 | 437 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 12073 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2018 | 41005 | 0.030 |
Why?
|
| Propensity Score | 1 | 2022 | 1781 | 0.030 |
Why?
|
| Animals | 11 | 2017 | 168768 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2009 | 5856 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2022 | 15535 | 0.030 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2014 | 82 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2021 | 1379 | 0.030 |
Why?
|
| Cattle | 1 | 1999 | 3922 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 2014 | 164 | 0.030 |
Why?
|
| Iron | 2 | 2014 | 1774 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2020 | 3914 | 0.030 |
Why?
|
| Osteotomy | 1 | 2018 | 822 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 7182 | 0.030 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 687 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2016 | 2505 | 0.030 |
Why?
|
| Anemia, Sideroblastic | 1 | 2012 | 101 | 0.030 |
Why?
|
| Child | 2 | 2018 | 77709 | 0.030 |
Why?
|
| Warfarin | 1 | 2020 | 1497 | 0.030 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 18111 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2017 | 9145 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2021 | 2241 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 57776 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2017 | 2726 | 0.030 |
Why?
|
| Blastocyst | 1 | 2014 | 424 | 0.020 |
Why?
|
| Menorrhagia | 1 | 2010 | 63 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 1312 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 9647 | 0.020 |
Why?
|
| Fibrosis | 1 | 2017 | 2029 | 0.020 |
Why?
|
| Yeasts | 1 | 2011 | 284 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2016 | 987 | 0.020 |
Why?
|
| Mice | 6 | 2014 | 81201 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3616 | 0.020 |
Why?
|
| Platelet Membrane Glycoprotein IIb | 1 | 2009 | 53 | 0.020 |
Why?
|
| K562 Cells | 1 | 2011 | 635 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 3480 | 0.020 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2009 | 189 | 0.020 |
Why?
|
| Xenopus | 1 | 2011 | 712 | 0.020 |
Why?
|
| Reference Values | 1 | 2016 | 4982 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2021 | 2987 | 0.020 |
Why?
|
| Regulatory Elements, Transcriptional | 1 | 2009 | 186 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2008 | 12207 | 0.020 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2009 | 157 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2012 | 2556 | 0.020 |
Why?
|
| Protein Stability | 1 | 2009 | 556 | 0.020 |
Why?
|
| Ploidies | 1 | 2008 | 281 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 6896 | 0.020 |
Why?
|
| Hospitals | 1 | 2021 | 3954 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 2184 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 2727 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2008 | 281 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2009 | 906 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2014 | 2126 | 0.020 |
Why?
|
| Protein Binding | 2 | 2009 | 9384 | 0.020 |
Why?
|
| Amino Acid Sequence | 2 | 2008 | 13814 | 0.020 |
Why?
|
| Prednisone | 1 | 2010 | 1574 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8642 | 0.020 |
Why?
|
| Young Adult | 3 | 2018 | 56429 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 21833 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 1950 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 16690 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2020 | 4600 | 0.020 |
Why?
|
| Leiomyoma | 1 | 2010 | 730 | 0.020 |
Why?
|
| Cell Count | 1 | 2009 | 1856 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10252 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2011 | 13035 | 0.020 |
Why?
|
| Biological Transport | 1 | 2009 | 2120 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2008 | 1202 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2008 | 2050 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 4208 | 0.020 |
Why?
|
| Oxygen | 1 | 2016 | 4189 | 0.020 |
Why?
|
| Rats | 2 | 2013 | 24252 | 0.020 |
Why?
|
| Sex Factors | 1 | 2018 | 10400 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 2010 | 1301 | 0.010 |
Why?
|
| Species Specificity | 1 | 2008 | 2478 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2008 | 2839 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2008 | 2256 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4751 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3486 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 1970 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 11031 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2009 | 3702 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 1549 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2018 | 7730 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 5181 | 0.010 |
Why?
|
| Transfection | 1 | 2009 | 5895 | 0.010 |
Why?
|
| Age Factors | 1 | 2018 | 18373 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 3921 | 0.010 |
Why?
|
| Binding Sites | 1 | 2009 | 6111 | 0.010 |
Why?
|
| Embryonic Stem Cells | 1 | 2008 | 1295 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2009 | 2504 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 2009 | 2073 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 6171 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2009 | 2566 | 0.010 |
Why?
|
| Base Sequence | 1 | 2011 | 12797 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 3773 | 0.010 |
Why?
|
| Genotype | 1 | 2014 | 12952 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2016 | 21748 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2009 | 2509 | 0.010 |
Why?
|
| Pregnancy | 1 | 1999 | 29144 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29060 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 25039 | 0.010 |
Why?
|
| Adolescent | 2 | 2018 | 85779 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 23336 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2020 | 53290 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 40075 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20130 | 0.010 |
Why?
|
| Cell Line | 1 | 2008 | 16000 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 9445 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 16367 | 0.010 |
Why?
|
| Mutation | 1 | 2011 | 29786 | 0.000 |
Why?
|